Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

LY 2157299

CAS 700874-72-2

912477-03-3

C22H19N5O  MW 369.42

Purity: 99%

Soluble in DMSO 

Ordering Information:

Cat. No. Axon 1491    Prime Source

Qty1:  2 mg (research sample) / €99  $129

Qty2:  5 mg (research sample) / €145  $189

Promotion: 2 x 5 mg @ €220  $286

Qty3: 25 mg (research sample) / €545  $709

Promotion: 2 x 25 mg @ €720  $936

Qty4: on request

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for payment and tech support.

Biological Activity:   Orally active transforming growth factor beta receptor (TGF-βR) kinase inhibitor under clinical development; IC50 values to be 86 nm (TβR1) and 2 nM (TβR2) respectively.   References:   L Bueno et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur. J. Cancer. 2008, 44(1), 142-150. [online]   Z Liu et al. VEGF and inhibitors of TGFβ type-I receptor kinase synergistically promote blood-vessel formation by inducing 5-integrin expression. J. Cell Sci. 2009, 122, 3294-3302. [online]   P Workman. New cancer drugs in the horizon. Fut. Oncology 2005, 1(3), 315-318. [online]     Chemical Name: 4-[2-(6-Methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxylic acid amide

LY 2157299 | TGF-β inhibitor | Axon Medchem | Axon 1491 | LY2157299

Axon Ligands ^TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.

axonmedchem.com © 2012